O	0	7	Overall
O	8	16	Survival
O	17	21	with
B-intervention	22	33	Palbociclib
I-intervention	34	37	and
I-intervention	38	49	Fulvestrant
O	50	52	in
O	53	61	Advanced
O	62	68	Breast
O	69	75	Cancer
O	75	76	.

O	77	80	The
O	81	87	cyclin
O	87	88	-
O	88	97	dependent
O	98	104	kinase
O	105	106	4
O	107	110	and
O	111	112	6
O	113	114	(
O	114	118	CDK4
O	118	119	/
O	119	120	6
O	120	121	)
O	122	131	inhibitor
O	132	143	palbociclib
O	143	144	,
O	145	147	in
O	148	159	combination
O	160	164	with
O	165	176	fulvestrant
O	177	184	therapy
O	184	185	,
O	186	194	prolongs
O	195	206	progression
O	206	207	-
O	207	211	free
O	212	220	survival
O	221	226	among
O	227	235	patients
O	236	240	with
O	241	248	hormone
O	248	249	-
O	249	257	receptor
O	257	258	-
O	258	266	positive
O	266	267	,
O	268	273	human
O	274	283	epidermal
O	284	290	growth
O	291	297	factor
O	298	306	receptor
O	307	308	2
O	309	310	(
O	310	314	HER2
O	314	315	)
O	315	316	-
O	316	324	negative
O	325	333	advanced
O	334	340	breast
O	341	347	cancer
O	347	348	.

O	349	351	We
O	352	358	report
O	359	362	the
O	363	370	results
O	371	373	of
O	374	375	a
O	376	388	prespecified
O	389	397	analysis
O	398	400	of
O	401	408	overall
O	409	417	survival
O	417	418	.

O	419	421	We
O	422	430	randomly
O	431	439	assigned
B-eligibility	440	448	patients
I-eligibility	449	453	with
I-eligibility	454	461	hormone
I-eligibility	461	462	-
I-eligibility	462	470	receptor
I-eligibility	470	471	-
I-eligibility	471	479	positive
I-eligibility	479	480	,
I-eligibility	481	485	HER2
I-eligibility	485	486	-
I-eligibility	486	494	negative
I-eligibility	495	503	advanced
I-eligibility	504	510	breast
I-eligibility	511	517	cancer
I-eligibility	518	521	who
I-eligibility	522	525	had
I-eligibility	526	537	progression
I-eligibility	538	540	or
I-eligibility	541	548	relapse
I-eligibility	549	555	during
I-eligibility	556	564	previous
I-eligibility	565	574	endocrine
I-eligibility	575	582	therapy
O	583	585	to
O	586	593	receive
B-intervention	594	605	palbociclib
I-intervention	606	610	plus
I-intervention	611	622	fulvestrant
O	623	625	or
B-control	626	633	placebo
I-control	634	638	plus
I-control	639	650	fulvestrant
O	650	651	.

O	652	654	We
O	655	663	analyzed
O	664	671	overall
O	672	680	survival
O	680	681	;
O	682	685	the
O	686	692	effect
O	693	695	of
O	696	707	palbociclib
O	708	717	according
O	718	720	to
O	721	724	the
O	725	737	prespecified
O	738	752	stratification
O	753	760	factors
O	761	763	of
O	764	772	presence
O	773	775	or
O	776	783	absence
O	784	786	of
O	787	798	sensitivity
O	799	801	to
O	802	811	endocrine
O	812	819	therapy
O	819	820	,
O	821	829	presence
O	830	832	or
O	833	840	absence
O	841	843	of
O	844	852	visceral
O	853	863	metastatic
O	864	871	disease
O	871	872	,
O	873	876	and
O	877	887	menopausal
O	888	894	status
O	894	895	;
O	896	899	the
O	900	908	efficacy
O	909	911	of
O	912	922	subsequent
O	923	932	therapies
O	933	938	after
O	939	946	disease
O	947	958	progression
O	958	959	;
O	960	963	and
O	964	970	safety
O	970	971	.

O	972	977	Among
B-total-participants	978	981	521
O	982	990	patients
O	991	994	who
O	995	1004	underwent
O	1005	1018	randomization
O	1018	1019	,
O	1020	1023	the
B-outcome	1024	1030	median
I-outcome	1031	1038	overall
I-outcome	1039	1047	survival
O	1048	1051	was
B-iv-cont-median	1052	1054	34
I-iv-cont-median	1054	1055	.
I-iv-cont-median	1055	1056	9
I-iv-cont-median	1057	1063	months
O	1064	1065	(
O	1065	1067	95
O	1067	1068	%
O	1069	1079	confidence
O	1080	1088	interval
O	1089	1090	[
O	1090	1092	CI
O	1092	1093	]
O	1093	1094	,
O	1095	1097	28
O	1097	1098	.
O	1098	1099	8
O	1100	1102	to
O	1103	1105	40
O	1105	1106	.
O	1106	1107	0
O	1107	1108	)
O	1109	1111	in
O	1112	1115	the
O	1116	1127	palbociclib
O	1127	1128	-
O	1128	1139	fulvestrant
O	1140	1145	group
O	1146	1149	and
B-cv-cont-median	1150	1152	28
I-cv-cont-median	1152	1153	.
I-cv-cont-median	1153	1154	0
I-cv-cont-median	1155	1161	months
O	1162	1163	(
O	1163	1165	95
O	1165	1166	%
O	1167	1169	CI
O	1169	1170	,
O	1171	1173	23
O	1173	1174	.
O	1174	1175	6
O	1176	1178	to
O	1179	1181	34
O	1181	1182	.
O	1182	1183	6
O	1183	1184	)
O	1185	1187	in
O	1188	1191	the
O	1192	1199	placebo
O	1199	1200	-
O	1200	1211	fulvestrant
O	1212	1217	group
O	1218	1219	(
O	1219	1225	hazard
O	1226	1231	ratio
O	1232	1235	for
O	1236	1241	death
O	1241	1242	,
O	1243	1244	0
O	1244	1245	.
O	1245	1247	81
O	1247	1248	;
O	1249	1251	95
O	1251	1252	%
O	1253	1255	CI
O	1255	1256	,
O	1257	1258	0
O	1258	1259	.
O	1259	1261	64
O	1262	1264	to
O	1265	1266	1
O	1266	1267	.
O	1267	1269	03
O	1269	1270	;
O	1271	1272	P
O	1272	1273	=
O	1273	1274	0
O	1274	1275	.
O	1275	1277	09
O	1277	1278	;
O	1279	1287	absolute
O	1288	1298	difference
O	1298	1299	,
O	1300	1301	6
O	1301	1302	.
O	1302	1303	9
O	1304	1310	months
O	1310	1311	)
O	1311	1312	.

O	1313	1317	CDK4
O	1317	1318	/
O	1318	1319	6
O	1320	1329	inhibitor
O	1330	1339	treatment
O	1340	1345	after
O	1346	1349	the
O	1350	1360	completion
O	1361	1363	of
O	1364	1367	the
O	1368	1373	trial
O	1374	1381	regimen
O	1382	1390	occurred
O	1391	1393	in
O	1394	1396	16
O	1396	1397	%
O	1398	1400	of
O	1401	1404	the
O	1405	1413	patients
O	1414	1416	in
O	1417	1420	the
O	1421	1428	placebo
O	1428	1429	-
O	1429	1440	fulvestrant
O	1441	1446	group
O	1446	1447	.

O	1448	1453	Among
O	1454	1457	410
O	1458	1466	patients
O	1467	1471	with
O	1472	1483	sensitivity
O	1484	1486	to
O	1487	1495	previous
O	1496	1505	endocrine
O	1506	1513	therapy
O	1513	1514	,
O	1515	1518	the
B-outcome	1519	1525	median
I-outcome	1526	1533	overall
I-outcome	1534	1542	survival
O	1543	1546	was
B-iv-cont-median	1547	1549	39
I-iv-cont-median	1549	1550	.
I-iv-cont-median	1550	1551	7
I-iv-cont-median	1552	1558	months
O	1559	1560	(
O	1560	1562	95
O	1562	1563	%
O	1564	1566	CI
O	1566	1567	,
O	1568	1570	34
O	1570	1571	.
O	1571	1572	8
O	1573	1575	to
O	1576	1578	45
O	1578	1579	.
O	1579	1580	7
O	1580	1581	)
O	1582	1584	in
O	1585	1588	the
O	1589	1600	palbociclib
O	1600	1601	-
O	1601	1612	fulvestrant
O	1613	1618	group
O	1619	1622	and
B-cv-cont-median	1623	1625	29
I-cv-cont-median	1625	1626	.
I-cv-cont-median	1626	1627	7
I-cv-cont-median	1628	1634	months
O	1635	1636	(
O	1636	1638	95
O	1638	1639	%
O	1640	1642	CI
O	1642	1643	,
O	1644	1646	23
O	1646	1647	.
O	1647	1648	8
O	1649	1651	to
O	1652	1654	37
O	1654	1655	.
O	1655	1656	9
O	1656	1657	)
O	1658	1660	in
O	1661	1664	the
O	1665	1672	placebo
O	1672	1673	-
O	1673	1684	fulvestrant
O	1685	1690	group
O	1691	1692	(
O	1692	1698	hazard
O	1699	1704	ratio
O	1704	1705	,
O	1706	1707	0
O	1707	1708	.
O	1708	1710	72
O	1710	1711	;
O	1712	1714	95
O	1714	1715	%
O	1716	1718	CI
O	1718	1719	,
O	1720	1721	0
O	1721	1722	.
O	1722	1724	55
O	1725	1727	to
O	1728	1729	0
O	1729	1730	.
O	1730	1732	94
O	1732	1733	;
O	1734	1742	absolute
O	1743	1753	difference
O	1753	1754	,
O	1755	1757	10
O	1757	1758	.
O	1758	1759	0
O	1760	1766	months
O	1766	1767	)
O	1767	1768	.

O	1769	1772	The
B-outcome	1773	1779	median
I-outcome	1780	1788	duration
I-outcome	1789	1791	of
I-outcome	1792	1802	subsequent
I-outcome	1803	1810	therapy
O	1811	1814	was
O	1815	1822	similar
O	1823	1825	in
O	1826	1829	the
O	1830	1833	two
O	1834	1840	groups
O	1840	1841	,
O	1842	1845	and
O	1846	1849	the
B-outcome	1850	1856	median
I-outcome	1857	1861	time
I-outcome	1862	1864	to
I-outcome	1865	1868	the
I-outcome	1869	1876	receipt
I-outcome	1877	1879	of
I-outcome	1880	1892	chemotherapy
O	1893	1896	was
B-iv-cont-median	1897	1899	17
I-iv-cont-median	1899	1900	.
I-iv-cont-median	1900	1901	6
I-iv-cont-median	1902	1908	months
O	1909	1911	in
O	1912	1915	the
O	1916	1927	palbociclib
O	1927	1928	-
O	1928	1939	fulvestrant
O	1940	1945	group
O	1945	1946	,
O	1947	1949	as
O	1950	1958	compared
O	1959	1963	with
B-cv-cont-median	1964	1965	8
I-cv-cont-median	1965	1966	.
I-cv-cont-median	1966	1967	8
I-cv-cont-median	1968	1974	months
O	1975	1977	in
O	1978	1981	the
O	1982	1989	placebo
O	1989	1990	-
O	1990	2001	fulvestrant
O	2002	2007	group
O	2008	2009	(
O	2009	2015	hazard
O	2016	2021	ratio
O	2021	2022	,
O	2023	2024	0
O	2024	2025	.
O	2025	2027	58
O	2027	2028	;
O	2029	2031	95
O	2031	2032	%
O	2033	2035	CI
O	2035	2036	,
O	2037	2038	0
O	2038	2039	.
O	2039	2041	47
O	2042	2044	to
O	2045	2046	0
O	2046	2047	.
O	2047	2049	73
O	2049	2050	;
O	2051	2052	P
O	2052	2053	<
O	2053	2054	0
O	2054	2055	.
O	2055	2058	001
O	2058	2059	)
O	2059	2060	.

O	2061	2063	No
O	2064	2067	new
B-outcome	2068	2074	safety
I-outcome	2075	2082	signals
O	2083	2087	were
O	2088	2096	observed
O	2097	2101	with
O	2102	2104	44
O	2104	2105	.
O	2105	2106	8
O	2107	2113	months
O	2114	2116	of
O	2117	2123	follow
O	2123	2124	-
O	2124	2126	up
O	2126	2127	.

O	2128	2133	Among
O	2134	2142	patients
O	2143	2147	with
O	2148	2155	hormone
O	2155	2156	-
O	2156	2164	receptor
O	2164	2165	-
O	2165	2173	positive
O	2173	2174	,
O	2175	2179	HER2
O	2179	2180	-
O	2180	2188	negative
O	2189	2197	advanced
O	2198	2204	breast
O	2205	2211	cancer
O	2212	2215	who
O	2216	2219	had
O	2220	2231	sensitivity
O	2232	2234	to
O	2235	2243	previous
O	2244	2253	endocrine
O	2254	2261	therapy
O	2261	2262	,
O	2263	2272	treatment
O	2273	2277	with
O	2278	2289	palbociclib
O	2289	2290	-
O	2290	2301	fulvestrant
O	2302	2310	resulted
O	2311	2313	in
O	2314	2320	longer
B-outcome	2321	2328	overall
I-outcome	2329	2337	survival
O	2338	2342	than
O	2343	2352	treatment
O	2353	2357	with
O	2358	2365	placebo
O	2365	2366	-
O	2366	2377	fulvestrant
O	2377	2378	.

O	2379	2382	The
O	2383	2394	differences
O	2395	2397	in
O	2398	2405	overall
O	2406	2414	survival
O	2415	2417	in
O	2418	2421	the
O	2422	2428	entire
O	2429	2434	trial
O	2435	2440	group
O	2441	2445	were
O	2446	2449	not
O	2450	2461	significant
O	2461	2462	.

O	2463	2464	(
O	2464	2470	Funded
O	2471	2473	by
O	2474	2480	Pfizer
O	2480	2481	;
O	2482	2488	PALOMA
O	2488	2489	-
O	2489	2490	3
O	2491	2505	ClinicalTrials
O	2505	2506	.
O	2507	2510	gov
O	2511	2517	number
O	2517	2518	,
O	2519	2530	NCT01942135
O	2531	2532	.
O	2532	2533	)
O	2533	2534	.
